Edwards Lifesciences Corporation (NYSE:EW), a leading medical technology company specializing in heart valve therapies and critical care technologies with a market capitalization of $44.9 billion, has ...

Edwards Lifesciences Corp.’s posted fourth quarter results slightly ahead of expectations, but indicated that the first quarter of 2025 might not be as bright. The company expects growth for both its ...

2 Centre National de Référence pour le syndrome de Marfan et apparentés, Hôpital Bichat, AP-HP, Paris, France Background Bicuspid aortic valve (BAV) is related to aortic dilatation, but patterns/rates ...

As cavitation bubbles collapse, they produce shock waves inducing mechanical softening of the targeted calcified valve leaflet. Therapeutic dose was estimated as the mean acoustic focal energy (J/mm2) ...

Edwards enters 2025, its first full year as a purely structural heart company, in a strong position with major growth drivers in Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter ...

cardiology.washington.edu This review summaries the utility, application and data supporting use of cardiac magnetic resonance imaging (CMR) to evaluate and quantitate aortic regurgitation ... In ...

Endovascular Today (ISSN 1551-1944 print and ISSN 2689-792X online) is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the ...

Championship club Burnley are close to signing winger Marcus Edwards from Sporting Lisbon, talkSPORT understands. Edwards is set to join the Clarets on loan until the end of the 2024/25 season ...

We came across a bullish thesis on Edwards Lifesciences Corporation (EW) on Substack by Natan. In this article, we will summarize the bulls’ thesis on EW. Edwards Lifesciences Corporation (EW)'s ...

A critical component of Edwards' success is its leadership in the $7 billion transcatheter aortic valve replacement (TAVR) market, where it holds over 50% market share. This segment generates roughly ...

Stifel analyst Rick Wise upgraded Edwards from Hold to Buy, raising the price forecast to $90 from $75. Wise suggests that recent conversations with six Transcatheter aortic valve replacement ...